Treatment with either axi-cel or liso-cel provides potential to sustain disease-free survival in patients with LBCL, according to a study presented at the 2025 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR.
Findings from a subgroup analysis of ZUMA-7 support early referral to axi-cel therapy.
In a prospective study patients with Fanconi anemia were matched to healthy controls and underwent carotid artery ultrasound.
Patient-reported response is associated with overall response, total symptom score response, and failure-free survival.
In the TRANSCEND FL trial liso-cel has met primary and secondary endpoints for both MZL and FL with manageable safety.
Discussing the evolving role of selinexor in treatment of myeloproliferative neoplasms.
Advertisement
Podcasts
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Video Insights
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
Study finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
Yesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology